Galectin Therapeutics (GALT) Reports Q2 Loss of $0.14/Share

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.14), versus ($0.20) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• HSBC Raises S&P500 Target to 8,100
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth